Cumaraswamy, AA, Lewis, AM, Geletu, M, Todic, A, Diaz, DB, Cheng, XR, Brown, CE, Laister, RC, Muench, D, Kerman, K, Grimes, HL, Minden, MD and Gunning, PT (2014) Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Medicinal Chemistry Letters, 5 (11). pp. 1202-1206. ISSN 1948-5875
|
Accepted Version
Available under License In Copyright. Download (2MB) | Preview |
Abstract
© 2014 American Chemical Society. We herein report the design and synthesis of the first nanomolar binding inhibitor of STAT5 protein. Lead compound 13a, possessing a phosphotyrosyl-mimicking salicylic acid group, potently and selectively binds to STAT5 over STAT3, inhibits STAT5-SH2 domain complexation events in vitro, silences activated STAT5 in leukemic cells, as well as STAT5's downstream transcriptional targets, including MYC and MCL1, and, as a result, leads to apoptosis. We believe 13a represents a useful probe for interrogating STAT5 function in cells as well as being a potential candidate for advanced preclinical trials.
Impact and Reach
Statistics
Additional statistics for this dataset are available via IRStats2.